Datafin

Data-driven stock analysis platform for global investors.

Sitemap
HomeScreenerValuationSector Analysis
Resources
LibraryDatafin GuideMetric MethodologyValuation MethodologiesFAQPricingWho Is Datafin?Communication
Legal
Privacy PolicyTerms of UseCookie PolicyKVKK NoticeRefund Policy
Data Sources

Financial data sourced from official regulatory filings and verified market data providers. Metrics calculated using GAAP/IFRS standards.

Disclaimer

The analyses and visuals on this site are for informational purposes only and do not constitute investment advice.

Investment decisions involve risk. Verify data independently and consult a licensed advisor when needed.

© 2026 Datafin Financial Data Analysis Systems. All rights reserved.

Last updated: April 2026

PHR FINANCIAL STATEMENTS

Phreesia Inc — balance sheet, income statement and cash flow trends

PHRPhreesia Inc

🇺🇸 USA · NYSE · Healthcare · Health Information Services

Value itDuel
PriceFinancialsPeers

Income Statement

Quarterly progression — trailing-twelve-month values
RevenueNet Income
-200 M0200 M400 M202120222023202420252026

Profit Funnel

Q2 2026 · TTM
Revenue495.6 M $Gross Profit326.1 M $ · 66%Operating Income3.6 M $ · 1%Pre-tax Income-1 M $ · -0%Net Income9.2 M $ · 2%

Percentages are relative to revenue.

Key Figures

YoY change
Revenue495.6 M $+14.1%
Gross Profit326.1 M $+10.3%
Operating Income3.6 M $—
EBITDA42.4 M $—
Net Income9.2 M $—

Peer Comparison· Health Information Services

CompanyRev. GrowthGross MarginEBITDA MarginNet Margin
PHR14.1%65.8%8.6%1.9%
FONET53.5%39.8%49.6%26.0%
PME30.3%78.4%78.4%97.6%
Industry median7.1%63.4%12.4%1.5%
CompanyRev. GrowthGross MarginEBITDA MarginNet Margin
PHR14.1%65.8%8.6%1.9%
MDRX————
EVH-21.3%14.1%-16.7%-26.3%
HSTM6.6%64.9%22.4%6.4%
WEAV16.8%72.3%-3.0%-10.1%
NRC-1.9%55.9%20.1%6.5%
Industry median7.1%63.4%12.4%1.5%

Balance Sheet

Quarterly period-end values
Total AssetsTotal LiabilitiesEquity
0200 M400 M600 M202120222023202420252026

Capital Structure

Q2 2026
Total Assets666.1 M
  • Equity359.1 M $54%
  • Current Liabilities152.1 M $23%
  • Long-term Liabilities154.9 M $23%

Key Figures

YoY change
Total Assets666.1 M $+66.4%
Total Liabilities307.1 M $+159.8%
Total Equity359.1 M $+27.3%
Cash & ST Investments74.7 M $-17.8%
Total Debt92.6 M $+483.3%
Net Debt17.9 M $—

Peer Comparison· Health Information Services

CompanyCurrent RatioDebt/EquityNetDebt/EBITDAEquity/Assets
PHR1.7625.8%0.4253.9%
FONET2.312.5%-0.2190.9%
PME6.221.1%-1.1672.8%
Industry median1.8322.0%-0.0164.7%
CompanyCurrent RatioDebt/EquityNetDebt/EBITDAEquity/Assets
PHR1.7625.8%0.4253.9%
MDRX————
EVH1.32248.6%-2.6121.1%
HSTM0.974.0%-0.7566.7%
WEAV1.2461.6%2.8640.8%
NRC0.52578.2%2.7110.0%
Industry median1.8322.0%-0.0164.7%

Cash Flow Statement

Quarterly progression — trailing-twelve-month values
Operating Cash FlowCapital ExpendituresFree Cash Flow
-100 M0202120222023202420252026

Cash Flow Bridge

Q2 2026 · TTM
-50 M050 M87.9 M $Operating-149.7 M $Investing47.6 M $Financing-14.2 M $Net Change

Key Figures

YoY change
Operating Cash Flow87.9 M $+83.3%
Capital Expenditures15.1 M $-32.6%
Free Cash Flow72.7 M $+185.4%
Dividends Paid——

Peer Comparison· Health Information Services

CompanyCF MarginFCF MarginCapEx RatioCF/Net Income
PHR17.7%14.7%3.1%957.1%
FONET45.0%9.6%32.1%173.0%
PME56.5%56.3%0.2%57.9%
Industry median17.1%13.0%1.6%165.1%
CompanyCF MarginFCF MarginCapEx RatioCF/Net Income
PHR17.7%14.7%3.1%957.1%
MDRX———-73.6%
EVH1.8%0.1%1.7%-6.7%
HSTM20.3%19.2%1.1%318.2%
WEAV4.8%3.9%1.0%-48.2%
NRC19.5%12.6%6.9%298.7%
Industry median17.1%13.0%1.6%165.1%

Amounts are in the company’s reporting currency. Peer comparison tables use ratio-based metrics so currency differences do not distort the picture.

Go deeper on PHR

Run a DCF valuation

Full DCF model with editable assumptions

Start a head-to-head duel

Compare two stocks metric by metric

Filter in the stock screener

Build your own universe with 400+ metrics

Data on this page refreshes once per day. Price data as of Jul 7, 26. This content is for informational purposes only and is not investment advice.